| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| José C Fernández-García, Mora Murri, Leticia Coin-Aragüez, Juan Alcaide, Rajaa El Bekay, Francisco J Tinahone. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. Clinical endocrinology. vol 80. issue 5. 2014-12-18. PMID:23573808. |
obesity, insulin resistance and hyperglycaemia are significant confounders when glp-1 and pyy secretion is assessed. |
2014-12-18 |
2023-08-12 |
human |
| José C Fernández-García, Mora Murri, Leticia Coin-Aragüez, Juan Alcaide, Rajaa El Bekay, Francisco J Tinahone. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects. Clinical endocrinology. vol 80. issue 5. 2014-12-18. PMID:23573808. |
thus, we evaluated glp-1 and pyy response after fat load in morbidly obese patients with different degrees of insulin resistance and glycemic status. |
2014-12-18 |
2023-08-12 |
human |
| Aliasghar A Kiadaliri, Ulf G Gerdtham, Bjorn Eliasson, Katarina Steen Carlsso. Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 5. issue 2. 2014-12-18. PMID:25213800. |
this study aimed to assess the costs and benefits of three alternative second-line treatment strategies for swedish patients with type 2 diabetes mellitus (t2dm) who fail to reach glycated hemoglobin (hba1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (glp-1) receptor agonists, dipeptidyl peptidase-4 (dpp-4) inhibitors, and neutral protamine hagedorn (nph) insulin. |
2014-12-18 |
2023-08-13 |
Not clear |
| Jennifer Taher, Christopher L Baker, Carmelle Cuizon, Hassan Masoudpour, Rianna Zhang, Sarah Farr, Mark Naples, Celine Bourdon, Zdenka Pausova, Khosrow Adel. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Molecular metabolism. vol 3. issue 9. 2014-12-16. PMID:25506548. |
glp-1 receptor agonism ameliorates hepatic vldl overproduction and de novo lipogenesis in insulin resistance. |
2014-12-16 |
2023-08-13 |
Not clear |
| Jennifer Taher, Christopher L Baker, Carmelle Cuizon, Hassan Masoudpour, Rianna Zhang, Sarah Farr, Mark Naples, Celine Bourdon, Zdenka Pausova, Khosrow Adel. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. Molecular metabolism. vol 3. issue 9. 2014-12-16. PMID:25506548. |
recently, the incretin hormone glucagon-like peptide-1 (glp-1) has been implicated in ameliorating dyslipidemia associated with insulin resistance and reducing hepatic lipid stores. |
2014-12-16 |
2023-08-13 |
Not clear |
| Catherine Hajmrle, Mourad Ferdaoussi, Gregory Plummer, Aliya F Spigelman, Krista Lai, Jocelyn E Manning Fox, Patrick E MacDonal. SUMOylation protects against IL-1β-induced apoptosis in INS-1 832/13 cells and human islets. American journal of physiology. Endocrinology and metabolism. vol 307. issue 8. 2014-12-15. PMID:25139051. |
while increased sumoylation reduces β-cell exocytosis, insulin secretion, and responsiveness to glp-1, the impact of sumoylation on islet cell survival is unknown. |
2014-12-15 |
2023-08-13 |
mouse |
| Edward P Weiss, Nathaniel K Royer, Jonathan S Fisher, John O Holloszy, Luigi Fontan. Postprandial plasma incretin hormones in exercise-trained versus untrained subjects. Medicine and science in sports and exercise. vol 46. issue 6. 2014-12-08. PMID:24576859. |
after food ingestion, the incretin hormones, glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), are secreted by the intestines into circulation where they act on the pancreas to promote insulin secretion. |
2014-12-08 |
2023-08-12 |
human |
| Robert B Jones, Steven P Vickers, Sharon C Cheetham, Katie R Headland, Michael Mark, Thomas Klei. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. European journal of pharmacology. vol 729. 2014-12-03. PMID:24530555. |
linagliptin (1mg/kg po) improved glucose tolerance by increasing plasma glp-1 (active) and insulin secretion, whilst having no effect on body weight. |
2014-12-03 |
2023-08-12 |
rat |
| Robert B Jones, Steven P Vickers, Sharon C Cheetham, Katie R Headland, Michael Mark, Thomas Klei. Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats. European journal of pharmacology. vol 729. 2014-12-03. PMID:24530555. |
voglibose (1 and 10mg/kg po) reduced body weight, improved glycaemic control, reduced plasma insulin and increased total but not active glp-1. |
2014-12-03 |
2023-08-12 |
rat |
| Dean A Wacker, Ying Wang, Matthias Broekema, Karen Rossi, Steven O'Connor, Zhenqiu Hong, Ginger Wu, Sarah E Malmstrom, Chen-Pin Hung, Linda LaMarre, Anjaneya Chimalakonda, Lisa Zhang, Li Xin, Hong Cai, Cuixia Chu, Stephanie Boehm, Jacob Zalaznick, Randolph Ponticiello, Larisa Sereda, Song-Ping Han, Rachel Zebo, Bradley Zinker, Chiuwa Emily Luk, Richard Wong, Gerry Everlof, Yi-Xin Li, Chunyu K Wu, Michelle Lee, Steven Griffen, Keith J Miller, John Krupinski, Jeffrey A Rob. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. Journal of medicinal chemistry. vol 57. issue 18. 2014-12-03. PMID:25208139. |
gpr119 agonists have been shown to stimulate glucose-dependent insulin release by direct action in the pancreas and to promote secretion of the incretin glp-1 by action in the gastrointestinal tract. |
2014-12-03 |
2023-08-13 |
Not clear |
| Theodoros Angelopoulos, Alexander Kokkinos, Christos Liaskos, Nicholas Tentolouris, Kleopatra Alexiadou, Alexander Dimitri Miras, Iordanis Mourouzis, Despoina Perrea, Constantinos Pantos, Nicholas Katsilambros, Stephen R Bloom, Carel Wynard le Rou. The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus. BMJ open diabetes research & care. vol 2. issue 1. 2014-12-02. PMID:25452861. |
this crossover study compared the effect of slow and rapid eating patterns on hunger, fullness, glucose, insulin, and the appetite-related gut hormones peptide yy (pyy), glucagon-like peptide-1 (glp-1), and ghrelin in overweight and obese participants with type 2 diabetes mellitus (t2dm). |
2014-12-02 |
2023-08-13 |
human |
| Konrad Talbo. Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegenerative disease management. vol 4. issue 1. 2014-11-25. PMID:24640977. |
brain insulin resistance in alzheimer's disease and its potential treatment with glp-1 analogs. |
2014-11-25 |
2023-08-12 |
Not clear |
| Antonio Ceriello, Anna Novials, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Roberto Testa, Loredana Bucciarelli, Maurizio Rondinelli, Stefano Genoves. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes care. vol 37. issue 7. 2014-11-24. PMID:24667461. |
simultaneous glp-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. |
2014-11-24 |
2023-08-12 |
Not clear |
| Antonio Ceriello, Anna Novials, Silvia Canivell, Lucia La Sala, Gemma Pujadas, Katherine Esposito, Roberto Testa, Loredana Bucciarelli, Maurizio Rondinelli, Stefano Genoves. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes care. vol 37. issue 7. 2014-11-24. PMID:24667461. |
to test the hypothesis that the simultaneous administration of glp-1 and insulin may increase their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. |
2014-11-24 |
2023-08-12 |
Not clear |
| Xin-Sheng Han, Yong Huang, Hong-Jian Jing, Ai-Wu Zhang, Tao Jiang, Yu-Ming X. Neuroprotective effect of RYGB in Zucker fatty diabetic rats. International journal of clinical and experimental medicine. vol 7. issue 10. 2014-11-24. PMID:25419361. |
change in oral glucose tolerance, insulin sensitivity, and the plasma concentrations of insulin, glucagon, glucagon-like peptide-1 (glp-1) were measured. |
2014-11-24 |
2023-08-13 |
rat |
| Xin-Sheng Han, Yong Huang, Hong-Jian Jing, Ai-Wu Zhang, Tao Jiang, Yu-Ming X. Neuroprotective effect of RYGB in Zucker fatty diabetic rats. International journal of clinical and experimental medicine. vol 7. issue 10. 2014-11-24. PMID:25419361. |
in conclusion, the findings indicate that rygb ameliorates the severity of dpn, which may be associated with increased glp-1 and improved insulin sensitivity/action. |
2014-11-24 |
2023-08-13 |
rat |
| Gerhard H Scholz, Holger Fleischman. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic advances in endocrinology and metabolism. vol 5. issue 5. 2014-11-24. PMID:25419451. |
the combination of basal insulin and glucagon-like protein 1 receptor agonists (glp-1 ras) is a new intriguing therapeutic option for patients with type 2 diabetes. |
2014-11-24 |
2023-08-13 |
Not clear |
| Gerhard H Scholz, Holger Fleischman. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making. Therapeutic advances in endocrinology and metabolism. vol 5. issue 5. 2014-11-24. PMID:25419451. |
in our paper we discuss special features of combinations of short- or prandial-acting and long- or continuous-acting glp-1 ras like exenatide, lixisenatide and liraglutide with basal insulin in relation to different glycemic targets. |
2014-11-24 |
2023-08-13 |
Not clear |
| Thomas Forst, Peter Bramlag. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert opinion on pharmacotherapy. vol 15. issue 9. 2014-11-21. PMID:24837407. |
dipeptidyl peptidase-4 inhibitors increase circulating levels of glucagon-like peptide 1 (glp-1) and glucose dependent insulinotropic polypeptide regulating glucose-dependent insulin secretion. |
2014-11-21 |
2023-08-13 |
Not clear |
| Laurence G Trahair, Michael Horowitz, Chinmay S Marathe, Kylie Lange, Scott Standfield, Christopher K Rayner, Karen L Jone. Impact of gastric emptying to the glycemic and insulinemic responses to a 75-g oral glucose load in older subjects with normal and impaired glucose tolerance. Physiological reports. vol 2. issue 11. 2014-11-21. PMID:25413324. |
blood glucose, serum insulin and plasma glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) were measured, and the insulin sensitivity index (isi), and the disposition index (di), were calculated. |
2014-11-21 |
2023-08-13 |
human |